Navigation Links
Jiangbo Pharmaceuticals' Osteomyelitis Treatment Tablets to be Included in China's National Insurance Directory
Date:1/13/2010

LAIYANG, China, Jan. 13 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (OTC Bulletin Board: JGBO) (the "Company" or "Jiangbo"), a pharmaceutical company with its principal operations in China, today announced that its Osteomyelitis treatment tablets (Kang Gu Sui Yan Pian) has been included in the 2009 Edition of the National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Medicine Directory ("the Directory").

Jiangbo is the exclusive manufacturer of Osteomyelitis treatment tablets in China. This product is used to treat bone and bone marrow inflammations. It's a 100% herb-based traditional Chinese medicine. Most osteomyelitis patients currently use chemical drugs such as antibiotics for treatment which may develop drug resistance if the chemical drugs are taken over a long period of time. Chronic patients are also likely to need surgery which is a less preferable treatment for patients in China. Jiangbo's Osteomyelitis treatment tablets offer an alternative mild treatment and were clinically tested to be effective in treating long term osteomyelitis problems.

The Company has four other products which have been included in the Directory. They are Radix Isatidis Granules, Motherwort Herb Electuary (Yi Mu Cao Gao), Ciprofloxacin Hydrochloride tablets and Paracetamol tablets. Currently, the Company is producing limited quantities of these four products.

"The inclusion of Osteomyelitis treatment tablets in the 2009 Edition Directory is an important accomplishment for our Company," said Mr. Wubo Cao, the Company's Chief Executive Officer. "As its exclusive manufacture, we expect the inclusion of Osteomyelitis treatment tablets in the Directory to drive meaningful sales volume growth in future."

About Jiangbo Pharmaceuticals, Inc.

Jiangbo Pharmaceuticals is engaged in the research, development, production, marketing and sales of pharmaceutical products in China. The Company's operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong Province. Jiangbo produces both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. For additional information, please visit the Company's website ( http://www.jiangbopharma.com ).

Safe Harbor Statement

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, anticipated sales volume growth of the medicines, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

    For more information, please contact:

    Jiangbo Pharmaceuticals, Inc.
     Ms. Elsa Sung, CFO
     Phone: +1-954-727-8435
     Email: elsasung@jiangbo.com
     Web:   http://www.jiangbopharma.com

    CCG Investor Relations, Inc.
     Mr. Crocker Coulson, President
     Phone: +1-646-213-1915
     Email: crocker.coulson@ccgir.com
     Web:   http://www.ccgirasia.com

SOURCE Jiangbo Pharmaceuticals, Inc.

RELATED LINKS
http://www.jiangbopharma.com/

'/>"/>

SOURCE Jiangbo Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Jiangbo Pharmaceuticals Obtains Renewal of GMP Certificate
2. Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results
3. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for the First Quarter of Fiscal Year 2010
4. Oramed Pharmaceuticals Announces Filing of Two Registration Statements
5. Jazz Pharmaceuticals to Present at 2010 J.P. Morgan Healthcare Conference
6. Vion Pharmaceuticals Announces FDA Conclusion
7. VIA Pharmaceuticals Receives Delisting Notification From NASDAQ
8. Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
9. Smith & Nephew Completes Acquisition of the Assets of Nucryst Pharmaceuticals Corp.
10. Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
11. Isis Pharmaceuticals to Receive $10 Million From OncoGenex License of OGX-011 to Teva
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 2017 Global intravenous (IV) iron and oral iron ... growing at a CAGR of 5%. Iron ... to treat anemia or other iron deficiencies. Oral iron supplements ... However, in some cases, oral administrations are not capable of ... iron therapy comes into the picture. Global Intravenous ...
(Date:3/29/2017)... DES MOINES, Iowa , March 29, 2017 ... Iowa Lt. Gov. Kim Reynolds , Department of Public ... Control Policy Director Steve Lukan in announcing the ... at all CVS Pharmacy locations in Iowa.  CVS Health has ... that allows CVS Pharmacy to expand access to ...
(Date:3/29/2017)... March 29, 2017  Experts in the field ... devices like  Soberlink Systems  as a model for ... published in early 2017, concluded that remote blood ... managing patient recovery." The findings of ... Addiction Medicine, detail a range of variables that ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... The Professional ... it has enlisted New York City-based sports and entertainment marketing firm Leverage Agency ... sponsorship opportunities for the Professional Squash Association (PSA), which includes first-time ever title ...
(Date:3/29/2017)... ... 2017 , ... CHARM CITY RUN WELCOMES MERCY MEDICAL CENTER AS , BALTIMORE ... will serve as the official title sponsor of the Baltimore Women’s Classic, the largest ... of women will walk or run the course around the Baltimore Inner Harbor. Mercy ...
(Date:3/29/2017)... ... 30, 2017 , ... Sports Brand EXOUS Bodygear announced today a special sale ... for the remaining days of March, the price will be only $19.97. The EXOUS ... of just $10 (regular retail price $19.97). , The special promotional prices are to ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... with or without a referral to new patients from Burnaby, BC. Patients in ... other full mouth reconstruction services, can see the esteemed team at Wall Centre ...
(Date:3/29/2017)... ... March 29, 2017 , ... Dr. Angela Cotey, a noted general dentist in ... pediatric patients, with or without a referral. Dr. Cotey knows that interceptive orthodontics ... and experience. When patients receive early treatment, they may achieve straight teeth with less ...
Breaking Medicine News(10 mins):